Xarelto Lawsuit 2026: The $775M Settlement, Bleeding Risks & How to File
Xarelto (rivaroxaban) lawsuits ended in March 2019 when Bayer and Janssen Pharmaceuticals agreed to a $775 million settlement covering roughly 25,000 U.S. claims in MDL No. 2592, resolving one of the largest blood-thinner litigations in history.
Key Facts
- $775 million settlement announced March 25, 2019 — split evenly between Bayer and Janssen, with no admission of liability
- Approximately 25,000 lawsuits consolidated in MDL No. 2592 in the U.S. District Court for the Eastern District of Louisiana
- The manufacturers prevailed in all six bellwether trials before agreeing to settle
- Xarelto remains FDA-approved and is still prescribed in the United States
What Xarelto Is and Why It Drew Scrutiny
Xarelto (rivaroxaban) is an anticoagulant — a prescription drug that thins the blood to prevent clots. The FDA first approved it in July 2011 for stroke prevention in patients with atrial fibrillation, and later for treating deep vein thrombosis and pulmonary embolism and preventing clots after hip or knee replacement surgery. It belongs to a generation of drugs called direct oral anticoagulants, marketed as more convenient than warfarin because they required no routine blood monitoring. Plaintiffs alleged that this convenience came with a serious drawback: for years, no approved reversal agent existed to stop a Xarelto-related bleed. The FDA approved Andexxa (andexanet alfa), a reversal agent for rivaroxaban and apixaban, in May 2018.
The Litigation: MDL No. 2592
Thousands of injured patients and families filed lawsuits alleging that Xarelto caused severe internal bleeding, strokes, and blood clots, and that the makers downplayed the bleeding risk and failed to warn that a bleed could be impossible to stop quickly. The federal cases were consolidated as multidistrict litigation — MDL No. 2592 — before Judge Eldon E. Fallon in Louisiana. Before any settlement talks, the court held six bellwether trials, a small set of representative cases tried to signal how future juries might rule. The companies won all six.
The $775 Million Settlement
On March 25, 2019, Bayer and Janssen Pharmaceuticals (a Johnson & Johnson company) announced they would jointly pay $775 million — $387.5 million each — to resolve nearly all pending U.S. Xarelto claims, about 25,000 of them. Neither company admitted liability, and both publicly stood by the drug's safety, calling the deal a way to end costly, distracting litigation. Per Johnson & Johnson's SEC filings, the agreement became final in December 2019 and was funded in January 2020, with a court-appointed special master overseeing individual claim payments and appeals. Payments were substantially reduced for certain claimants, including those first prescribed Xarelto on or after December 1, 2015, or first injured on or after March 1, 2016.
Who Qualified for the Settlement
The settlement covered the approximately 25,000 pending cases, and it also extended to people who had retained a lawyer to investigate a Xarelto injury before March 11, 2019, as long as they registered their claim by March 28, 2019, and filed suit by April 4, 2019. Individual payouts were not publicly disclosed; in mass-tort settlements of this kind, compensation varies widely by case, and most settlement payments remain confidential.
What New Claims Look Like in 2026
The 2019 settlement closed the MDL, but it did not make Xarelto risk-free history. People injured by the drug in recent years may still have legal options — every state imposes a statute of limitations (a legal deadline for filing), and the clock typically runs from the injury or from when it was reasonably discovered. If you or a loved one suffered a serious bleed while taking Xarelto, a mass-tort attorney can evaluate whether your claim is timely and what evidence — pharmacy records, hospital records, prescriber notes — would support it. Be aware that state deadlines differ sharply: some states allow only one year from the injury for personal-injury claims, while others allow two or three, and a few recognize a "discovery rule" that starts the clock only when you reasonably learned the drug caused the harm. Because these rules interact in complicated ways, waiting to seek advice can be the costliest mistake of all.
How to Protect Your Rights Before Filing
Start by preserving every record: the prescription history, dates of the bleed or event, emergency-room and hospital records, and any communications with your doctor. Do not sign releases or accept insurance offers without legal review. Most pharmaceutical-injury lawyers work on contingency — you pay only if compensation is recovered — so an initial case review costs nothing. For context on how large drug-injury cases move through the courts, see Suboxone Lawsuit Update October 2026 and Tepezza Lawsuit Update October 2026.
Who Benefits From This — and Who Does Not
Who benefits most from this guide:
People who suffered severe, sometimes fatal internal bleeding after taking Xarelto when no approved reversal agent existed. How: plaintiffs alleged the drug caused severe bleeding with no approved reversal agent available at the time, since Andexxa was not FDA-approved until May 2018.
People with a timely new individual claim. How: the MDL closed after the 2019 settlement, but new individual claims are possible if the state's statute of limitations has not expired, and only a qualified attorney can evaluate a specific timeline.
People who can document the prescription, the bleeding event, and the timeline. How: those records are what distinguish a viable new claim from a closed settlement claim, since eligibility turns on when the injury occurred and when it was discovered.
Who does not benefit:
Anyone expecting to join the $775 million settlement now. How: that settlement covered roughly 25,000 pending claimants plus people who had retained counsel before March 11, 2019, registered by March 28, 2019, and filed suit by April 4, 2019, and it became final in December 2019.
Anyone assuming the bellwether trials favoured plaintiffs. How: the manufacturers prevailed in all six bellwether trials before agreeing to settle, so past trial results do not promise an outcome for a new claim.
Anyone taking Xarelto today with no bleeding injury documented. How: Xarelto remains FDA-approved and is still prescribed, and the claims described here centre on severe bleeding injuries, not on current use alone.
The earlier blood-thinner litigation with the same reversal-agent history is covered in our guide to the Pradaxa lawsuits.
FAQs
Is the Xarelto lawsuit still open in 2026?
The MDL closed after the 2019 settlement, but new individual claims are possible if the state's statute of limitations has not expired. Only a qualified attorney can evaluate your specific timeline.
Who qualified for the $775 million settlement?
The roughly 25,000 pending claimants plus people who had retained counsel before March 11, 2019, registered their claim by March 28, 2019, and filed suit by April 4, 2019.
What bleeding risks did the Xarelto lawsuits allege?
Plaintiffs alleged the drug caused severe, sometimes fatal internal bleeding with no approved reversal agent available at the time — Andexxa was not FDA-approved until May 2018.
Can I still sue over Xarelto in 2026?
Potentially, depending on when the injury occurred, when it was discovered, and your state's filing deadline. An attorney can determine whether a claim remains viable.
Who benefits most from a Xarelto claim evaluation?
People who suffered severe internal bleeding after taking Xarelto, especially before Andexxa was approved in May 2018, benefit most, provided the claim remains timely under their state's statute of limitations. The MDL closed after the 2019 settlement, so a viable case today is a new individual claim, not a share of the old settlement.
Who does not benefit, and how do I start a Xarelto evaluation?
People expecting to join the $775 million settlement, and people with no bleeding injury, do not benefit, because that settlement covered about 25,000 pending claims and became final in December 2019. Start by gathering prescription records, bleeding-event records, and a timeline of injury and discovery, and have a qualified attorney determine whether your state's deadline has expired.
This article is general information about a public legal settlement, not legal or medical advice. If you believe you were harmed by a prescription drug, consult a licensed attorney in your state. For explanatory videos on health and legal topics, see Problem Solved on YouTube.